Literature DB >> 29660324

Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Veeral Ajmera1, Charlie C Park1, Cyrielle Caussy2, Seema Singh1, Carolyn Hernandez1, Ricki Bettencourt1, Jonathan Hooker3, Ethan Sy3, Cynthia Behling4, Ronghui Xu5, Michael S Middleton3, Mark A Valasek6, Claire Faulkner1, Emily Rizo1, Lisa Richards1, Claude B Sirlin7, Rohit Loomba8.   

Abstract

Markers are needed to predict progression of nonalcoholic fatty liver disease (NAFLD). The proton density fat fraction, measured by magnetic resonance imaging (MRI-PDFF), provides an accurate, validated marker of hepatic steatosis; however, it is not clear whether the PDFF identifies patients at risk for NAFLD progression. We performed a follow-up study of 95 well-characterized patients with biopsy-proven NAFLD and examined the association between liver fat content and fibrosis progression. MRI-PDFF measurements were made at study entry (baseline). Biopsies were collected from patients at baseline and after a mean time period of 1.75 years. Among patients with no fibrosis at baseline, a higher proportion of patients in the higher liver fat group (MRI-PDFF ≥15.7%) had fibrosis progression (38.1%) than in the lower liver fat group (11.8%) (P = .067). In multivariable-adjusted logistic regression models (adjusted for age, sex, ethnicity, and body mass index), patients in the higher liver fat group had a significantly higher risk of fibrosis progression (multivariable-adjusted odds ratio 6.7; 95% confidence interval 1.01-44.1; P = .049). Our findings associate higher liver fat content, measured by MRI-PDFF, with fibrosis progression.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; NASH; Risk Factor; Steatosis

Mesh:

Substances:

Year:  2018        PMID: 29660324      PMCID: PMC6090543          DOI: 10.1053/j.gastro.2018.04.014

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

Review 1.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

2.  Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging.

Authors:  Arian Mashhood; Radha Railkar; Takeshi Yokoo; Yakir Levin; Lisa Clark; Sabrina Fox-Bosetti; Michael S Middleton; Jonathan Riek; Eunkyung Kauh; Bernard J Dardzinski; Donald Williams; Claude Sirlin; Norah J Shire
Journal:  J Magn Reson Imaging       Date:  2012-11-21       Impact factor: 4.813

3.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

4.  The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.

Authors:  Yaron Rotman; Christopher Koh; Joseph M Zmuda; David E Kleiner; T Jake Liang
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 5.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Janki Patel; Meera Soni; Larry J Prokop; Zobair Younossi; Giada Sebastiani; Mattias Ekstedt; Hannes Hagstrom; Patrik Nasr; Per Stal; Vincent Wai-Sun Wong; Stergios Kechagias; Rolf Hultcrantz; Rohit Loomba
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

6.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

7.  Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.

Authors:  Charlie C Park; Phirum Nguyen; Carolyn Hernandez; Ricki Bettencourt; Kimberly Ramirez; Lynda Fortney; Jonathan Hooker; Ethan Sy; Michael T Savides; Mosab H Alquiraish; Mark A Valasek; Emily Rizo; Lisa Richards; David Brenner; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterology       Date:  2016-10-27       Impact factor: 22.682

8.  Noninvasive fatty liver markers predict liver disease mortality in the U.S. population.

Authors:  Aynur Unalp-Arida; Constance E Ruhl
Journal:  Hepatology       Date:  2016-01-22       Impact factor: 17.425

9.  Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.

Authors:  Thuy-Anh Le; Joshua Chen; Christopher Changchien; Michael R Peterson; Yuko Kono; Heather Patton; Benjamin L Cohen; David Brenner; Claude Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

10.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

View more
  33 in total

1.  Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Veeral H Ajmera; Puneet Puri; Cynthia Li-Shin Hsu; Shirin Bassirian; Mania Mgdsyan; Seema Singh; Claire Faulkner; Mark A Valasek; Emily Rizo; Lisa Richards; David A Brenner; Claude B Sirlin; Arun J Sanyal; Rohit Loomba
Journal:  Gut       Date:  2018-12-19       Impact factor: 23.059

2.  Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography.

Authors:  Cyrielle Caussy; Meera Bhargava; Ida F Villesen; Natasja S Gudmann; Diana J Leeming; Morten A Karsdal; Claire Faulkner; Denny Bao; Amy Liu; Min-Tzu Lo; Ricki Bettencourt; Shirin Bassirian; Lisa Richards; David A Brenner; Chi-Hua Chen; Claude B Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2019-04-29       Impact factor: 17.425

Review 3.  Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

Authors:  Michelle T Long; Sanil Gandhi; Rohit Loomba
Journal:  Metabolism       Date:  2020-05-05       Impact factor: 8.694

4.  MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).

Authors:  Veeral H Ajmera; Edward Cachay; Christian Ramers; Irine Vodkin; Shirin Bassirian; Seema Singh; Neeraj Mangla; Richele Bettencourt; Jeannette L Aldous; Daniel Park; Daniel Lee; Jennifer Blanchard; Adrija Mamidipalli; Andrew Boehringer; Saima Aslam; Olof Dahlqvist Leinhard; Lisa Richards; Claude Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2019-06-18       Impact factor: 17.425

Review 5.  Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma.

Authors:  Guilherme Moura Cunha; Victoria Chernyak; Kathryn J Fowler; Claude B Sirlin
Journal:  J Hepatocell Carcinoma       Date:  2021-05-31

Review 6.  Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging.

Authors:  Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin
Journal:  Br J Radiol       Date:  2018-06-06       Impact factor: 3.039

7.  Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.

Authors:  Veeral H Ajmera; Edward R Cachay; Christian B Ramers; Shirin Bassirian; Seema Singh; Richele Bettencourt; Lisa Richards; Gavin Hamilton; Michael Middleton; Katie Fowler; Claude Sirlin; Rohit Loomba
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

Review 8.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

9.  Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.

Authors:  Georg Semmler; Katharina Wöran; Bernhard Scheiner; Lukas Walter Unger; Rafael Paternostro; Judith Stift; Philipp Schwabl; Theresa Bucsics; David Bauer; Benedikt Simbrunner; Albert Friedrich Stättermayer; Matthias Pinter; Michael Trauner; Thomas Reiberger; Mattias Mandorfer
Journal:  United European Gastroenterol J       Date:  2020-01-17       Impact factor: 4.623

10.  Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.

Authors:  Rohit Loomba; Brent A Neuschwander-Tetri; Arun Sanyal; Naga Chalasani; Anna Mae Diehl; Norah Terrault; Kris Kowdley; Srinivasan Dasarathy; David Kleiner; Cynthia Behling; Joel Lavine; Mark Van Natta; Michael Middleton; James Tonascia; Claude Sirlin
Journal:  Hepatology       Date:  2020-10-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.